Fly News Breaks for April 25, 2018
AMGN
Apr 25, 2018 | 09:23 EDT
Cowen analyst Eric Schmidt noted Amgen reported better than expected Q1 results and tweaked the lower end of its revenue guidance. The analyst said the guidance appears conservative in light of sales trends. Schmidt reiterated his Outperform rating and $204 price target on Amgen, noting he believes the shares remain undervalued.
News For AMGN From the Last 2 Days
AMGN
May 1, 2024 | 09:20 EDT
BMO Capital says that in a in a "surprise announcement," CytomX Therapeutics (CTMX) this morning announced it will provide an initial CX-904 Phase 1a dose escalation update when it reports Q1 results on May 8. CytomX had previously guided to CX-904 initial Phase 1a data in solid tumors in the second half of 2024, the analyst tells investors in a research note. The firm says the Phase 1a data is intended to inform a potential decision to initiate Phase 1b expansion cohorts in specific EGFR positive tumor types in conjunction with partner Amgen (AMGN). BMO expects the stock to react positively "given current levels" to the announcement. It has a Market Perform rating on CytomX with a $3.25 price target. The stock in premarket trading is up 93% to $3.15
